4-[1-Carboxy-3-(1-carboxyethoxy)-3-oxopropoxy]-2-methoxy-4-oxobutanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-[1-Carboxy-3-(1-carboxyethoxy)-3-oxopropoxy]-2-methoxy-4-oxobutanoic acid
• 英文别名: 4-[1-carboxy-3-(1-carboxyethoxy)-3-oxopropoxy]-2-methoxy-4-oxobutanoic acid
• 化学式: C₁₂H₁₆O₁₁
• 分子量: 336.25
• InChiKey: WJNKJYZOZXYJBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  23
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  174
• 氢给体数：
  3
• 氢受体数：
  11

文献信息

• DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER
  申请人：Patil Rameshwar

  公开号：US20140161762A1

  公开（公告）日：2014-06-12

  The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.
• US8785371B2
  申请人：——

  公开号：US8785371B2

  公开（公告）日：2014-07-22
• US9320807B2
  申请人：——

  公开号：US9320807B2

  公开（公告）日：2016-04-26
• US9629919B2
  申请人：——

  公开号：US9629919B2

  公开（公告）日：2017-04-25
• US9827325B2
  申请人：——

  公开号：US9827325B2

  公开（公告）日：2017-11-28